FI901949A0 - Syraresistant fgf-blandning och foerfarande foer behandling av saorbildande sjukdomar i matsmaeltningskanalen. - Google Patents

Syraresistant fgf-blandning och foerfarande foer behandling av saorbildande sjukdomar i matsmaeltningskanalen.

Info

Publication number
FI901949A0
FI901949A0 FI901949A FI901949A FI901949A0 FI 901949 A0 FI901949 A0 FI 901949A0 FI 901949 A FI901949 A FI 901949A FI 901949 A FI901949 A FI 901949A FI 901949 A0 FI901949 A0 FI 901949A0
Authority
FI
Finland
Prior art keywords
syraresistant
saorbildande
matsmaeltningskanalen
sjukdomar
fgf
Prior art date
Application number
FI901949A
Other languages
English (en)
Finnish (fi)
Inventor
Moses J Folkman
Koichi Kato
Original Assignee
Childrens Medical Center
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Takeda Chemical Industries Ltd filed Critical Childrens Medical Center
Publication of FI901949A0 publication Critical patent/FI901949A0/fi
Priority to FI943028A priority Critical patent/FI943028A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI901949A 1988-08-19 1990-04-18 Syraresistant fgf-blandning och foerfarande foer behandling av saorbildande sjukdomar i matsmaeltningskanalen. FI901949A0 (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI943028A FI943028A (fi) 1988-08-19 1994-06-22 Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23496688A 1988-08-19 1988-08-19
US07/382,263 US5175147A (en) 1988-08-19 1989-07-20 Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
PCT/US1989/003467 WO1990001941A1 (en) 1988-08-19 1989-08-11 Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract

Publications (1)

Publication Number Publication Date
FI901949A0 true FI901949A0 (fi) 1990-04-18

Family

ID=26928432

Family Applications (2)

Application Number Title Priority Date Filing Date
FI901949A FI901949A0 (fi) 1988-08-19 1990-04-18 Syraresistant fgf-blandning och foerfarande foer behandling av saorbildande sjukdomar i matsmaeltningskanalen.
FI943028A FI943028A (fi) 1988-08-19 1994-06-22 Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI943028A FI943028A (fi) 1988-08-19 1994-06-22 Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi

Country Status (16)

Country Link
US (2) US5175147A (es)
EP (1) EP0360006B1 (es)
JP (1) JP2501480B2 (es)
KR (1) KR920700040A (es)
CN (1) CN1040741A (es)
AT (1) ATE91628T1 (es)
CA (1) CA1330757C (es)
DE (1) DE68907679T2 (es)
DK (1) DK93890D0 (es)
ES (1) ES2058423T3 (es)
FI (2) FI901949A0 (es)
HU (1) HU207227B (es)
IE (1) IE63046B1 (es)
IL (1) IL91322A (es)
NO (1) NO901710L (es)
WO (1) WO1990001941A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
JPH0343088A (ja) * 1989-09-29 1991-02-25 Takeda Chem Ind Ltd ａＦＧＦ蛋白質の製造法
EP0406738A3 (en) * 1989-07-03 1991-08-14 Takeda Chemical Industries, Ltd. Production of acidic fgf protein
CA2020720A1 (en) * 1989-07-13 1991-01-14 Shigeko Yamazaki Method for the purification of therapeutically active recombinant acidic fibroblast growth factor
AUPN271295A0 (en) 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
US5972884A (en) * 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US6399569B1 (en) 1991-03-11 2002-06-04 Curis, Inc. Morphogen treatments for limiting proliferation of epithelial cells
JPH06506939A (ja) * 1991-04-12 1994-08-04 クリエイティブ　バイオモレキュルズ　インコーポレイテッド 血小板由来の成長因子に依る消化管潰瘍の治療方法
NO921495L (no) * 1991-04-16 1992-10-19 Seikagaku Kogyo Co Ltd Oligosakkarid og fremgangsmaate for dets fremstilling
US6190864B1 (en) * 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
AU685058B2 (en) * 1992-06-16 1998-01-15 Selective Genetics, Inc. Recombinant production of saporin-containing proteins
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
FR2718023B1 (fr) * 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5531880A (en) * 1994-09-13 1996-07-02 Microelectronics And Computer Technology Corporation Method for producing thin, uniform powder phosphor for display screens
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
AU2001284914B2 (en) * 2000-08-15 2006-02-09 New Technologies Holdings Pte Ltd Phage-dependent superproduction of biologically active protein and peptides
US7754686B2 (en) * 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
EP3752174A4 (en) * 2018-02-13 2021-11-17 University of Florida Research Foundation, Incorporated ANALOGUES OF FIBROBLASTS GROWTH FACTOR AND THEIR USES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296100A (en) * 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
EP0105014B1 (en) * 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
JPS6028999A (ja) * 1983-06-30 1985-02-14 Maruho Kk 細胞増殖促進作用を有するたんぱく質、その組成物と製造方法
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
CA1207239A (en) * 1984-08-10 1986-07-08 Upendra K. Banik Gastrointestinal compositions
JPS6172947A (ja) * 1984-09-18 1986-04-15 Takasago Thermal Eng Co Ltd クリ−ンル−ムの形成法およびこの方法に使用する空気調和設備ユニツト
IE66689B1 (en) * 1985-09-12 1996-01-24 Scios Nova Inc Recombinant fibroblast growth factors
DK122687A (da) * 1986-03-14 1987-09-15 Takeda Chemical Industries Ltd Polypeptid, dna og anvendelse deraf
CA1294546C (en) * 1986-04-23 1992-01-21 John S. Sundsmo Wound healing composition containing collagen
NZ220917A (en) * 1986-07-11 1991-05-28 Merck & Co Inc Human and bovine acidic fibroblast growth factor vectors, hosts and compositions
CA1323317C (en) * 1987-01-16 1993-10-19 Allen R. Banks Production of fibroblast growth factor
EP0377579A1 (en) * 1987-07-07 1990-07-18 California Biotechnology, Inc. Recombinant fibroblast growth factors
WO1989004832A1 (en) * 1987-11-24 1989-06-01 Amgen Inc. Analogs of fibroblast growth factor
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
JPH0240399A (ja) * 1988-07-27 1990-02-09 Takeda Chem Ind Ltd 線維芽細胞増殖因子ムテインの複合体あるいは組成物

Also Published As

Publication number Publication date
HU207227B (en) 1993-03-29
DE68907679D1 (de) 1993-08-26
EP0360006A2 (en) 1990-03-28
IE892664L (en) 1990-02-19
ATE91628T1 (de) 1993-08-15
IL91322A (en) 1994-12-29
DE68907679T2 (de) 1994-01-27
AU630111B2 (en) 1992-10-22
HUT55638A (en) 1991-06-28
EP0360006B1 (en) 1993-07-21
FI943028A0 (fi) 1994-06-22
CN1040741A (zh) 1990-03-28
JPH03505736A (ja) 1991-12-12
CA1330757C (en) 1994-07-19
WO1990001941A1 (en) 1990-03-08
US5401721A (en) 1995-03-28
IE63046B1 (en) 1995-03-22
AU4218989A (en) 1990-03-23
EP0360006A3 (en) 1990-04-04
HU895785D0 (en) 1990-12-28
NO901710D0 (no) 1990-04-18
IL91322A0 (en) 1990-03-19
DK93890A (da) 1990-04-17
NO901710L (no) 1990-04-18
JP2501480B2 (ja) 1996-05-29
ES2058423T3 (es) 1994-11-01
DK93890D0 (da) 1990-04-17
FI943028A (fi) 1994-06-22
KR920700040A (ko) 1992-02-19
US5175147A (en) 1992-12-29

Similar Documents

Publication Publication Date Title
FI901949A0 (fi) Syraresistant fgf-blandning och foerfarande foer behandling av saorbildande sjukdomar i matsmaeltningskanalen.
NO894296D0 (no) Fremgangsmaate for behandling av leddgikt og betennelsessykdommer.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ATE81978T1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
FI94028B (fi) Laite nenäsairauksien diagnoosia ja hoitoa varten
NO911952L (no) Behandling av tilstander og sykdommer samt midler derfor.
DE3686582D1 (de) Behandlung einer krankheit vom aids-typ.
SE8804256D0 (sv) Homogen kiselnitridsintrad kropp och foerfarande foer tillverkning av densamma
DK465488D0 (da) Farmaceutisk praeparat indeholdende en triazol-forbindelse
UA15913A (uk) Засіб для лікуваhhя запальhих захворюваhь стравоходу та запальhих виразкових захворювань шлуhково-кишкового тракту
DE3851971D1 (de) Verwendung antigener Substanzen zur Prophylaxe oder Therapie von Störungen und Krankheiten im Verdauungstrakt von Tieren und Menschen.
FI830523L (fi) Anti-inflammatoriska och/eller smaerta lindrande 2,3-diaryl-5-halotiofener
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
TR23707A (tr) 4-hidroksiasetofenon'nun aritilmasi icin usul
FI891210A0 (fi) Tiosulfinsyraderivat, deras anvaendning vid inflammationssjukdomar samt laekemedel innehaollande dessa aemnen.
EP0293925A3 (en) Compound active in cardiovasular therapy
DE69712287T2 (de) Verwendung von Sulbutiamin zur Behandlung von psychomotorischen oder psychointellektuellen Beschwerden
NO884635D0 (no) Fremgangsmaate for behandling av most.
LV5179A3 (lv) Preparats "etoksidins" teju kunga un zarnu slimibu profilaksei un arstesanai
NO893324D0 (no) Behandling av maligne tumorer med 8-kloradenosin-3',5'-cyklisk fosfat, 8-aminoadenosin-3',5'-cyklisk fosfat og fremstilling derav.
IT8765205V0 (it) Trattamento curativo preventivo con tro l'eudothia parassitica (cancro corticale) del castagno
IL66699A0 (en) Method for diagnosing and for the therapeutic treatment of tumors and/or infections diseases of different types with alkaloidcompounds
NO902968D0 (no) Fremgangsmaate for behandling av boreslam.

Legal Events

Date Code Title Description
FD Application lapsed
MM Patent lapsed

Owner name: TAKEDA CHEMICAL INDUSTRIES, LTD.

Owner name: CHILDREN S MEDICAL CENTER CORPORATION